Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,061,352 papers from all fields of science
Search
Sign In
Create Free Account
ivacaftor
Known as:
3-quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-
, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
, N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
10 relations
Broader (3)
Aminophenols
Chloride Channel Agonists
Quinolones
Chloride Channel Activation Potentiators [MoA]
ivacaftor / lumacaftor
ivacaftor 125 MG / lumacaftor 200 MG Oral Tablet [ORKAMBI]
ivacaftor 150 MG Oral Tablet [Kalydeco]
Narrower (3)
Kalydeco
ORKAMBI
VX-770
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2022
2022
Ivacaftor
P. Davis
,
Uma Yasothan
,
Peter Kirkpatrick
Nature reviews. Drug discovery
2022
Corpus ID: 245710254
In January 2012, ivacaftor (Kalydeco; Vertex Pharmaceuticals), a small-molecule potentiator of the cystic fibrosis transmembrane…
Expand
2019
2019
Comparative Bioavailability of a New Fixed DoseCombination Tablet Containing Lumacaftor/Ivacaftor in Healthy Subjects: A Randomized,Single-Dose, 2-Way Crossover Study
Yerino Gustavo
,
Feleder Ethel
,
+7 authors
Jaime Emilio
2019
Corpus ID: 203819169
Lumacaftor and ivacaftor, a CFTR modulator that comprises both a CFTR corrector and potentiator, is indicated as a fixed dose…
Expand
2016
2016
The effect of treatment with ivacaftor on the respiratory microbial composition in the upper and lower airways
M. Kristensen
,
K. W. Groot
,
+4 authors
C. Ent
2016
Corpus ID: 78543422
The 30th Annual North American Cystic Fibrosis Conference, Orange County Convention Center, Orlando, Florida, October 27–29, 2016
Review
2015
Review
2015
Medications to Enhance CFTR Activity
T. Chin
2015
Corpus ID: 93672640
Since the basic defect in cystic fibrosis (CF) involves a defective cell surface protein controlling chloride channel transport…
Expand
2015
2015
ivacaftor intermediates and preparation and use
叶天健
,
陆修伟
,
郁光亮
,
何思
2015
Corpus ID: 102987495
The present invention provides a method for preparing an intermediate ivacaftor comprising the compound (7) to esterification…
Expand
2014
2014
False dawn for cystic fibrosis disease modifiers?
D. Holmes
Nature reviews. Drug discovery
2014
Corpus ID: 7122816
Recent results have cast doubt over how effective a breakthrough class of cystic fibrosis drugs can be in patients with the most…
Expand
2013
2013
Ivacaftor. Uncertain harm-benefit balance.
Prescrire international
2013
Corpus ID: 25826090
Cystic fibrosis is a serious genetic disease due to mutations in the gene encoding CFTR (Cystic FibrosisTransmembrane conductance…
Expand
Review
2013
Review
2013
Challenges in pharmacogenetics
I. Cascorbi
,
O. Bruhn
,
A. Werk
European Journal of Clinical Pharmacology
2013
Corpus ID: 253765092
The attempt to optimize drug treatment of patients by using evidenced-based medicine considering individual physiological and…
Expand
2012
2012
Ivacaftor approved for cystic fibrosis
K. Traynor
2012
Corpus ID: 75293012
FDA on January 31 announced the approval of ivacaftor, an oral therapy that the agency called a breakthrough in personalized…
Expand
2012
2012
Straight talk with... Robert Beall
E. Dolgin
Nature Network Boston
2012
Corpus ID: 673176
'Venture philanthropy' has become a buzz term in the nonprofit sector over the past decade, but the concept was completely new to…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE